title: Bruton's tyrosine kinase: oncotarget in myeloma.
abstract: Our findings therefore provide a strong rationale for investigating Btk inhibitors in MM and WM to target both tumor cells and their supporting BM microenvironment and thereby both suppress tumor cell growth and abrogate MM-induced bone disease.
authors.forename: Yu-Tzu
authors.initials: YT
authors.lastname: Tai
authors.forename: Kenneth C
authors.initials: KC
authors.lastname: Anderson
mesh_terms: D000225:Adenine / Q000031:analogs & derivatives; D000077329:Agammaglobulinaemia Tyrosine Kinase; D000818:Animals; D048708:Cell Growth Processes / Q000187:drug effects; D004195:Disease Models, Animal; D006801:Humans; D051379:Mice; D058990:Molecular Targeted Therapy / Q000379:methods; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000201:enzymology* / Q000473:pathology; D010880:Piperidines; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D008258:Waldenstrom Macroglobulinemia / Q000188:drug therapy / Q000201:enzymology
chemical_list: D010880:Piperidines; D011720:Pyrazoles; D011743:Pyrimidines; C551803:ibrutinib; D011505:Protein-Tyrosine Kinases; D000077329:Agammaglobulinaemia Tyrosine Kinase; C000625949:BTK protein, human; C000625951:Btk protein, mouse; D000225:Adenine